170 related articles for article (PubMed ID: 18347114)
1. Biological activities of novel gyrase inhibitors of the aminocoumarin class.
Anderle C; Stieger M; Burrell M; Reinelt S; Maxwell A; Page M; Heide L
Antimicrob Agents Chemother; 2008 Jun; 52(6):1982-90. PubMed ID: 18347114
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis.
Galm U; Heller S; Shapiro S; Page M; Li SM; Heide L
Antimicrob Agents Chemother; 2004 Apr; 48(4):1307-12. PubMed ID: 15047534
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Alt S; Mitchenall LA; Maxwell A; Heide L
J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis.
Flatman RH; Eustaquio A; Li SM; Heide L; Maxwell A
Antimicrob Agents Chemother; 2006 Apr; 50(4):1136-42. PubMed ID: 16569821
[TBL] [Abstract][Full Text] [Related]
5. New aminocoumarin antibiotics as gyrase inhibitors.
Heide L
Int J Med Microbiol; 2014 Jan; 304(1):31-6. PubMed ID: 24079980
[TBL] [Abstract][Full Text] [Related]
6. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth.
Hooper DC; Wolfson JS; McHugh GL; Winters MB; Swartz MN
Antimicrob Agents Chemother; 1982 Oct; 22(4):662-71. PubMed ID: 6295263
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of inhibition of DNA gyrase by ES-1273, a novel DNA gyrase inhibitor.
Oyamada Y; Yamagishi J; Kihara T; Yoshida H; Wachi M; Ito H
Microbiol Immunol; 2007; 51(10):977-84. PubMed ID: 17951987
[TBL] [Abstract][Full Text] [Related]
8. Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action.
Flatman RH; Howells AJ; Heide L; Fiedler HP; Maxwell A
Antimicrob Agents Chemother; 2005 Mar; 49(3):1093-100. PubMed ID: 15728908
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo production of new aminocoumarins by a combined biochemical, genetic, and synthetic approach.
Galm U; Dessoy MA; Schmidt J; Wessjohann LA; Heide L
Chem Biol; 2004 Feb; 11(2):173-83. PubMed ID: 15123279
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B.
Laurin P; Ferroud D; Klich M; Dupuis-Hamelin C; Mauvais P; Lassaigne P; Bonnefoy A; Musicki B
Bioorg Med Chem Lett; 1999 Jul; 9(14):2079-84. PubMed ID: 10450985
[TBL] [Abstract][Full Text] [Related]
13. Altering gene expression by aminocoumarins: the role of DNA supercoiling in Staphylococcus aureus.
Schröder W; Bernhardt J; Marincola G; Klein-Hitpass L; Herbig A; Krupp G; Nieselt K; Wolz C
BMC Genomics; 2014 Apr; 15():291. PubMed ID: 24734910
[TBL] [Abstract][Full Text] [Related]
14. Aminocoumarins mutasynthesis, chemoenzymatic synthesis, and metabolic engineering.
Heide L
Methods Enzymol; 2009; 459():437-55. PubMed ID: 19362650
[TBL] [Abstract][Full Text] [Related]
15. Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance.
Gross CH; Parsons JD; Grossman TH; Charifson PS; Bellon S; Jernee J; Dwyer M; Chambers SP; Markland W; Botfield M; Raybuck SA
Antimicrob Agents Chemother; 2003 Mar; 47(3):1037-46. PubMed ID: 12604539
[TBL] [Abstract][Full Text] [Related]
16. The interaction between coumarin drugs and DNA gyrase.
Maxwell A
Mol Microbiol; 1993 Aug; 9(4):681-6. PubMed ID: 8231802
[TBL] [Abstract][Full Text] [Related]
17. Streptococcus pneumononiae gyrase ATPase: development and validation of an assay for inhibitor discovery and characterization.
Miller JR; Herberg JT; Tomilo M; McCroskey MC; Feilmeier BJ
Anal Biochem; 2007 Jun; 365(1):132-43. PubMed ID: 17395144
[TBL] [Abstract][Full Text] [Related]
18. Discoordinate gene expression of gyrA and gyrB in response to DNA gyrase inhibition in Escherichia coli.
Neumann S; Quiñones A
J Basic Microbiol; 1997; 37(1):53-69. PubMed ID: 9090126
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose.
Ferroud D; Collard J; Klich M; Dupuis-Hamelin C; Mauvais P; Lassaigne P; Bonnefoy A; Musicki B
Bioorg Med Chem Lett; 1999 Oct; 9(19):2881-6. PubMed ID: 10522711
[TBL] [Abstract][Full Text] [Related]
20. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
